Medical Cannabis and Cannabinoids
October 13, 2026
Taylor M. McGillis, Hannah P Stevenson, Willow Leland et al.
Cannabidiol (CBD) is a non-intoxicating phytocannabinoid with purported benefits across a range of pediatric conditions. However, the relative nascency of its integration in human populations has precluded a longitudinal safety assessment when used during different developmental periods. We hypothesized that CBD’s pharmacodynamic actions underlying the purported therapeutic effects could impact...
Clinical Therapeutics
September 2026
Jonathon K. Lisano, Luiza Rosa, Greg Giordano et al.
Emerging research indicates that the use of cannabis products, particularly those higher in cannabidiol (CBD), may be anxiolytic. Physical activity is another modality observed to have anxiolytic effects. Despite evidence of cannabis and physical activity being paired together, there is limited research on the possible synergistic effects of physical activity and cannabis use on reductions in...
Psychopharmacology
September 1, 2026
Renée Martin-Willett, Samantha N. Melendez, Kent E. Hutchison et al.
RATIONALE An estimated two-thirds of medical cannabis users in the United States are motivated by chronic pain, but clinical guidance remains guarded as to whether the potential benefit of cannabinoids for pain outweighs potential risks, such as effects on cognition. OBJECTIVES In a study where participants experienced benefits of cannabinoids for pain and tension, we evaluated cannabis effects...
Neurochemical Research
August 27, 2026
Kazutoshi Yonemura, Nobue Kitanaka, Kazuo Tomita et al.
Cannabis, widely used for both medical and non-medical purposes, primarily contains Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Δ9-THC is the main driver of cannabis abuse and of psychological and physical dependence, whereas CBD has limited abuse potential and is even being investigated as a treatment for cannabis use disorder and other conditions. This review aims to clarify how...
Journal of Cannabis Research
August 26, 2026
Ario Safaeian, Kaylen M. Young, John G. Howland et al.
Abstract Background Cannabis use has increased in recent years due to legalization. Smoking cannabis leads to inhalation of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in addition to other particles and gas in the smoke matrix as a result of combustion. The effect of THC on breathing pattern and metabolism has been characterized, but the influence of CBD and the smoke matrix on...
Neuroscience & Biobehavioral Reviews
August 20, 2026
Lucy Chester, Heidar Sharafi, Amani Mahroug et al.
Research on the pharmacokinetic influence of cannabidiol (CBD) on delta-9-tetrahydrocannabinol (THC) has produced equivocal results. We conducted a systematic search following PRISMA guidelines (last search: 24th November 2025, PROSPERO: CRD42023480695). Included studies were acute dosing trials that administered a) a single, fixed dose of THC and b) a matched dose of THC co-administered with...
Frontiers in Pharmacology
August 10, 2026
N. Miguel-Ramiro, N. Lamanna-Rama, M. Casquero-Veiga et al.
Background Disruptions in the gut-brain-microbiota axis are increasingly linked to psychiatric disorders. While cannabinoids possess immunomodulatory and neuroprotective properties, their impact on the microbial architecture during critical neurodevelopmental periods remains poorly understood. This exploratory study investigated whether adolescent treatment with delta-9-tetrahydrocannabinol...
Journal of Psychopharmacology
August 5, 2026
BACKGROUND: Cannabidiol (CBD) has emerged as a potential antipsychotic treatment, acting as a negative allosteric modulator of cannabinoid type-1 (CB1) receptors within the endocannabinoid system. Although previous neuroimaging studies have shown that CBD induces changes in aberrant brain activity and functional connectivity (FC) in psychosis, they have not directly integrated information about...
Archives of Psychiatry and Mental Health
July 29, 2026
Diamond Onyekachi Okoroezi
Aim: This systematic review and meta-analysis examined the neuropsychiatric effects of cannabis, focusing on the contrasting roles of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). It evaluated their associations with psychiatric outcomes, assessed the therapeutic potential of cannabis-based products (CBPs), and identified evidence gaps relevant to clinical practice and mental health...
The Journal of Organic Chemistry
July 24, 2026
Sirilak Kongkaew, Waraporn Parasuk, Vudhichai Parasuk
In this study, a reaction pathway for converting the psychoactive compound Δ9-THC into the nonpsychoactive cannabidiol (CBD) was proposed. Related cannabinoids, including Δ8-THC and cannabinol (CBN), were also examined. The transformation proceeds via two key steps: (i) hydrogen elimination and cyclic ether ring cleavage, and (ii) hydrolysis to form hydroxyl groups, facilitated by boron...
Journal of Psychopharmacology
July 15, 2026
Lucy Chester, François-Olivier Hebert, Pamela Lachance-Touchette et al.
BACKGROUND Cannabidiol (CBD) is widely consumed in low-dose products. However, evidence for its psychotropic effects at non-clinical doses is sparse and inconsistent. AIMS To characterise the acute behavioural effects of low-dose synthetic CBD in healthy volunteers. We hypothesised that 200 mg of CBD would produce a greater peak pleasant drug effect than a placebo. METHODS In a triple-blind,...
bioRxiv
July 2, 2026
Alba Cáceres-Rodríguez, Daniela Iezzi, Olivier Lassalle et al.
preprint
Background Prenatal cannabidiol (CBD) consumption is increasing, driven by a perception of safety relative to Δ9-tetrahydrocannabinol (THC). However, the neurodevelopmental risks of gestational CBD remain largely uncharacterized. Methods Using a sex-disaggregated framework, we investigated adult (P100–140) mouse offspring following in utero exposure (GD5-18; 3 mg/kg) to THC or CBD. Behavioral...
Journal of Neuroendocrinology
July 1, 2026
F. B. Caruso, M. A. Severo, Annalisa Colucci et al.
The aim of this study was to investigate the effects of cannabidiol (CBD) on memory deficits induced by ovariectomy and to directly compare its effects with those of hormone therapy, in order to better understand potential shared mechanisms related to menopause‐associated cognitive decline, with a particular focus on the endocannabinoid system. Three‐month‐old female Wistar rats were randomly...
Drug and Alcohol Dependence
July 1, 2026
Daniel L. Hall, Edward Chesney, Claire Mokrysz et al.
The presence of cannabidiol (CBD) in cannabis may alter cannabinoid pharmacokinetics, however previous research has produced mixed results. Furthermore, no prior research has explored how cannabinoid pharmacokinetics are moderated by age. Using vaporised and inhaled cannabis, we aimed to (1) examine the effect of CBD on the plasma concentration of delta-9-tetrahydrocannabinol (THC) and its...
Frontiers in Pharmacology
June 29, 2026
Laura Gálvez-melero, Sandra Ledesma-Corvi, C. Bis-Humbert et al.
There is a need for characterizing more efficacious therapeutic strategies for glioblastoma multiforme to overcome treatment resistance to the standardized use of temozolomide as well as to better treat its debilitating comorbidities like depression. In this context, combination therapies, particularly cannabidiol with temozolomide exhibited additive or synergistic anti-tumor effects, capable...
Brazilian Journal of Psychiatry
June 16, 2026
Daniel B.a. Prado, Matheus T. Rossignoli, Rafael N. Ruggiero et al.
Objective: Current treatments for schizophrenia (SZ) are often not effective for all symptoms, with sex-dependent effects poorly understood. Cannabidiol (CBD) and sodium nitroprusside (SNP) have emerged as potential prophylactic options. We evaluated their efficacy in preventing positive, negative, and cognitive deficits in a ketamine (KET) rodent model of SZ in both sexes. Methods: Wistar rats...
Psychoactives
June 8, 2026
Fizza Mitter, Anton Sheptooha, Janni Leung et al.
Post-traumatic stress disorder (PTSD) remains inadequately treated by existing pharmacological and psychological interventions, prompting growing interest in psychedelic-assisted psychotherapy. Although randomised controlled trials have evaluated several psychedelic agents for PTSD, to our knowledge, no prior PTSD-specific synthesis has quantitatively examined multiple agent classes within a...
Physiological research
May 12, 2026
Marcel Bochin, Čestmír Vejmola, Vlastimil Koudelka et al.
Cannabinoids modulate brain network activity, yet the spatial organization and temporal evolution of their electrophysiological effects remain insufficiently characterized in animal models. Here, we investigated how acute oral administration of ?9-tetrahydrocannabinol (THC; 10 mg/kg), cannabidiol (CBD; 10 mg/kg), and their combination influences resting-state EEG dynamics in freely moving rats....
Alcohol and Alcoholism
March 17, 2026
Ieva Poceviciute, Martynas Arbaciauskas, Rokas Buisas et al.
Previous studies have demonstrated that the endocannabinoid system plays a significant role in the development of alcohol use disorder (AUD), and CB1 receptor antagonists/inverse agonists show promise as a novel AUD pharmacotherapy. However, these compounds failed in clinical trials due to the severe psychiatric side effects. Non-psychoactive phytocannabinoids may have a better safety profile...
Biological Psychiatry
March 16, 2026
Xianglian Wang, Jing Xia, Heyi Luo et al.
Ketamine produces rapid antidepressant and antidepressant-like effects in both humans and animal models. However, its therapeutic benefits are tempered by psychoactive side effects, such as hyperlocomotion associated with enhanced dopaminergic activity in the ventral tegmental area (VTA). We tested the therapeutic effect of cannabidiol (CBD) on locomotor activity after systemic (30 mg/kg) or...